Advertisement

Topics

FDA Grants Breakthrough Therapy Designation to Imfinzi for Non-Small Cell Lung Cancer

13:23 EDT 31 Jul 2017 | Speciality Pharma Journal

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Imfinzi (durvalumab) for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy. Sean Bohen, Executive Vice President, Global Medicines …

Original Article: FDA Grants Breakthrough Therapy Designation to Imfinzi for Non-Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Breakthrough Therapy Designation to Imfinzi for Non-Small Cell Lung Cancer"

Quick Search
Advertisement
 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...